Cardiac Biomarkers in Pediatric Cardiomyopathy

描述（由申请人提供）：这是一个研究项目资助（R01）申请心脏生物标志物在小儿心肌病。在这份拨款建议书中，将有三个具体目标。第一个将试图确定临床重要性的既定和新的 新诊断（偶发）扩张型心肌病儿童的心脏生物标志物。第二项研究旨在评估胶原代谢的心脏生物标志物在确定心肌纤维化（如心脏MRI所示）和舒张功能障碍（如超声心动图所示）中的临床效用，这些心肌纤维化和舒张功能障碍均见于新诊断和现有的特发性或家族性肥厚型心肌病儿童病例。第三个也是最后一个目标将集中在确定心脏生物标志物的纵向变化是否与临床稳定的扩张型或肥厚型心肌病儿童心力衰竭分级恶化相关。这些研究将显著增加我们对小儿心肌病的理解，提出新的研究领域，并改善患者管理，因为它涉及到确定小儿心肌病患者最合适的循证临床护理。

DESCRIPTION (provided by applicant): This is a research project grant (R01) application for Cardiac Biomarkers in Pediatric Cardiomyopathy. In this grant proposal, there will be three specific aims. The first will attempt to determine the clinical importance of established and novel cardiac biomarkers in children with newly diagnosed (incident) dilated cardiomyopathy. The second will aim to assess the clinical utility of cardiac biomarkers of collagen metabolism in determining the presence of myocardial fibrosis, as established by cardiac MRI, and diastolic dysfunction, as established by echocardiography in both newly diagnosed and existing cases of idiopathic or familial hypertrophic cardiomyopathy in children. The third and final aim will focus on determining whether longitudinal changes in cardiac biomarkers are associated with worsening heart failure class in clinically stable children with dilated or hypertrophic cardiomyopathy. These studies will significantly increase our understanding of pediatric cardiomyopathy, suggest new areas of research, and improve patient management as it relates to determining the most appropriate evidence-based clinical care for pediatric cardiomyopathy patients.